Platinum-resistant Ovarian Cancer
📧 Sign up to get email alerts when something new happens for Platinum-resistant Ovarian Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer [Phase 2]
Phase 2 trial evaluating Adebrelimab combined with non-platinum chemotherapy and Fuzuloparib for recurrent platinum-resistant ovarian cancer…
-
CLINICAL_TRIALS trial_result · 2024-08-15Clinical Trial Update: A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) [Phase 2]
Phase 2 study MK-2140-002 evaluating Zilovertamab vedotin (VLS-101) in solid tumors including triple-negative breast cancer and non-small-ce…
-
CLINICAL_TRIALS research · 2024-08-07Clinical Trial Update: A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer [Phase 2]
A Phase 2 trial investigating two standard doses of bevacizumab in combination with chemotherapy for epithelial ovarian cancer, including pl…
-
CLINICAL_TRIALS trial_result · 2024-07-24Clinical Trial Update: First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b [Phase 1]
XMT-1536, an investigational NaPi2b-targeting agent from Mersana Therapeutics, completed a first-in-human Phase 1 dose-escalation study in c…
-
CLINICAL_TRIALS research · 2024-07-19Clinical Trial Update: A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer [Phase 2]
A Phase 2 clinical trial update describes a study of QL1706 combined with albumin-bound paclitaxel and bevacizumab for platinum-resistant re…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 trial of DSP-7888 Dosing Emulsion in combination with immune checkpoint inhibitors in adults with advanced solid tumors was termin…
-
CLINICAL_TRIALS trial_result · 2023-11-13Clinical Trial Update: First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b [Phase 1, Phase 2]
First-in-human study of XMT-1536 in cancers likely to express NaPi2b, including platinum-resistant ovarian cancer and metastatic non-small c…
-
CLINICAL_TRIALS trial_result · 2023-10-30Clinical Trial Update: Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer [Phase 3]
Phase 3 trial of Batiraxcept (AVB-S6-500) plus paclitaxel in platinum-resistant recurrent ovarian cancer was terminated.
-
CLINICAL_TRIALS trial_result · 2023-08-07Clinical Trial Update: Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer [Phase 2]
Phase 2 trial evaluating plasmid Elenagen in combination with gemcitabine for platinum-resistant ovarian cancer; status and results are not …
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) [Phase 3]
Phase 3 trial of VB-111 plus paclitaxel versus paclitaxel alone in recurrent platinum-resistant ovarian cancer has completed.
-
CLINICAL_TRIALS trial_result · 2022-04-04Clinical Trial Update: Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer [Phase 2]
A Phase 2 clinical trial evaluating albumin-bound paclitaxel in combination with bevacizumab for platinum-resistant recurrent ovarian cancer…
-
CLINICAL_TRIALS trial_result · 2021-12-08Clinical Trial Update: A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer [Phase 3]
Phase 3 trial comparing TQB2450 with Anlotinib capsules versus Paclitaxel weekly for relapsed platinum-resistant ovarian cancer.
-
CLINICAL_TRIALS trial_result · 2020-11-25Clinical Trial Update: Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer [Phase 2]
Phase 2 clinical trial evaluating dual therapy with Anlotinib and Niraparib for platinum-resistant recurrent ovarian cancer.
-
CLINICAL_TRIALS trial_result · 2020-08-20Clinical Trial Update: Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer [Phase 2]
Phase 2 trial evaluating cediranib plus olaparib in recurrent platinum-resistant ovarian cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-04-24Clinical Trial Update: A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer [Phase 1, Phase 2]
Phase I/II trial of VB-111 with paclitaxel for platinum-resistant ovarian cancer has completed.
-
CLINICAL_TRIALS trial_result · 2019-04-04Clinical Trial Update: Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer [Phase 1, Phase 2]
Phase 1/2 trial of CRS-207 with epacadostat in platinum-resistant ovarian, fallopian, or peritoneal cancer has been terminated; results post…
-
CLINICAL_TRIALS trial_result · 2019-03-19Clinical Trial Update: A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer [Phase 2]
Phase 2 trial investigating ABT-263 as a single agent in women with platinum-resistant or refractory recurrent ovarian cancer has completed.
-
CLINICAL_TRIALS trial_result · 2014-01-07Clinical Trial Update: Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer [Phase 1, Phase 2]
A phase 1/2 trial evaluating a chemo-immunotherapy regimen of gemcitabine, interferon-alpha 2b, and p53 SLP in platinum-resistant recurrent …